纳米载体药物递送系统在动脉粥样硬化治疗中的研究进展
x

请在关注微信后,向客服人员索取文件

篇名: 纳米载体药物递送系统在动脉粥样硬化治疗中的研究进展
TITLE: Research progress of nanocarrier-based drug delivery systems in the treatment of atherosclerosis
摘要: 纳米载体药物递送系统可通过调控药物的体内分布与释放行为,为动脉粥样硬化(AS)的病灶靶向干预提供新的研究策略。现有研究表明,聚合物与脂质纳米载体、细胞膜包裹系统及微环境响应型递药策略可通过调节巨噬细胞功能、促进胆固醇外排、控制炎症与氧化应激等途径干预AS的病理进程,部分递药系统尝试通过联合递送和诊疗一体化实现多靶点协同干预,还有部分纳米载体药物递送系统通过提高病灶药物富集来调节相关病理过程,但其长期安全性、病灶靶向稳定性、规模化制备及临床增量获益仍有待验证。未来需加强递送机制与病理特征的匹配,建立药动学和安全性的评价体系,为纳米载体药物递送系统的临床转化提供依据。
ABSTRACT: Nanocarrier-based drug delivery systems can provide new research strategies for targeted intervention at atherosclerosis (AS) lesions by regulating the in vivo distribution and release behavior of drugs. Existing studies have shown that polymeric and lipid nanocarriers, cell membrane-coated systems, and microenvironment-responsive drug delivery strategies can intervene in the pathological progression of AS by modulating macrophage function, promoting cholesterol efflux, and controlling inflammation and oxidative stress; some systems have attempted to achieve multi-target synergistic intervention through combined delivery and theranostics; some drug delivery systems can improve drug enrichment in lesions and modulate related pathological processes. However, their long-term safety, lesion-targeting stability, scale-up manufacturing, and incremental clinical benefit remain to be validated. In the future, it is necessary to strengthen the matching between delivery mechanisms and pathological features and to establish evaluation systems for pharmacokinetics and safety, thereby providing a basis for the clinical translation of nanocarrier-based drug delivery systems.
期刊: 2026年第37卷第20期
作者: 贺茜影;卫靖靖;马腾;苏帆;郑红梅;李晓曼;王小梅
AUTHORS: HE Xiying,WEI Jingjing,MA Teng,SU Fan,ZHENG Hongmei,LI Xiaoman,WANG Xiaomei
关键字: 动脉粥样硬化;纳米载体药物递送系统;仿生纳米载体;斑块微环境;临床转化
KEYWORDS: Atherosclerosis;nanocarrier-based drug delivery systems;biomimetic nanocarriers;plaque microenvironment;clinical translation
阅读数: 15 次
本月下载数: 0 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!